Core Insights - The global diabetes patient population is projected to reach 589 million by 2024, with China having the highest number of patients aged 20-79 at 148 million, expected to rise to 168 million by 2050 [1][2] - Continuous Glucose Monitoring (CGM) technology is rapidly replacing traditional methods due to its accuracy and convenience, becoming a key growth area in diabetes management [1][3] Industry Overview - The domestic CGM market is divided into two main camps: imported brands like Abbott and domestic companies such as Sanofi and Yuyue Medical, which are competing by lowering costs and enhancing product differentiation [2][4] - The CGM market is expected to grow significantly, with a projected market size of 71.8 billion yuan by 2025 and a compound annual growth rate of 14.49% until 2032, reaching 185.2 billion yuan [3][4] Company Performance - Sanofi reported a revenue of 3.453 billion yuan in the first three quarters, an increase of 8.52%, with a net cash flow from operating activities of 537 million yuan, up 33.25% [4] - Yuyue Medical has invested 2.375 billion yuan in R&D from 2020 to 2024, with CGM products becoming a significant growth driver, achieving a revenue of 6.545 billion yuan in the first three quarters of 2025 [4][5] Technological Advancements - The integration of AI in CGM products is enhancing their capabilities, with Yuyue Medical's new Anytime series achieving global leading technical standards [5][6] - The CGM technology is evolving from simple monitoring to a comprehensive diabetes management system, enabling personalized interventions based on data analysis [6][9] Market Dynamics - Domestic CGM companies are rapidly gaining market share by offering products at 30%-50% lower prices than international competitors, aided by favorable healthcare policies [2][4] - The shift from low-cost market filling to comprehensive capability building is evident, with domestic firms focusing on both mid-range and high-end market segments [6][9] Challenges and Opportunities - Domestic CGM companies face challenges such as regulatory compliance and operational costs, particularly in decentralized healthcare settings [7][8] - There is a need for improved training and data integration in grassroots healthcare to enhance the effectiveness of CGM products [8][9] Future Outlook - The CGM market is poised for significant growth, driven by technological advancements and increasing demand for chronic disease management solutions [3][9] - The potential for Chinese CGM companies to transition from domestic players to global competitors hinges on overcoming regulatory hurdles and enhancing product capabilities [7][9]

大成景恒混合A（090019）成立日期2012年6月15日，最新规模6.94亿。今年以来收益46.93%，同类排 名1332/8140；近一年收益40.02%，同类排名1229/8056；成立以来收益393.36%。 11月14日，之江生物涨5%，截至发稿，报23.94元/股，成交5660.03万元，换手率1.25%，总市值46.00亿 元。 资料显示，上海之江生物科技股份有限公司位于上海市闵行区陈行公路2168号9号楼，成立日期2005年4 月18日，上市日期2021年1月18日，公司主营业务涉及分子诊断试剂及仪器设备的研发、生产和销售。 主营业务收入构成为：核酸检测试剂盒86.47%，其它11.99%，分子诊断仪器1.54%。 从之江生物十大流通股东角度 数据显示，大成基金旗下1只基金位居之江生物十大流通股东。大成景恒混合A（090019）三季度持有 股数90.92万股，持股数量与上期相比不变，占流通股的比例为0.47%。根据测算，今日浮盈赚取约 103.65万元。 大成景恒混合A（090019）基金经理为苏秉毅。 截至发稿，苏秉毅累计任职时间13年283天，现任基金资产总规模19亿元，任职期间最佳基金回 ...

大博医疗所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：医疗器械、机器人概 念、口腔医疗、3D打印、中盘等。 截至9月30日，大博医疗股东户数2.28万，较上期增加17.38%；人均流通股12673股，较上期减少 14.80%。2025年1月-9月，大博医疗实现营业收入18.76亿元，同比增长22.69%；归母净利润4.25亿元， 同比增长77.03%。 分红方面，大博医疗A股上市后累计派现14.42亿元。近三年，累计派现3.07亿元。 机构持仓方面，截止2025年9月30日，大博医疗十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股1245.63万股，相比上期增加668.36万股。博时医疗保健混合A（050026）位居第六大流通 股东，持股183.66万股，相比上期减少110.10万股。南方中证1000ETF（512100）位居第九大流通股 东，持股75.69万股，相比上期增加100.00股。 11月14日，大博医疗盘中上涨2.02%，截至10:14，报50.56元/股，成交4807.82万元，换手率0.33%，总 市值209.33亿元。 资金流向方面，主力资金净流入185.28 ...

Group 1 - A-share market opened lower and fluctuated, with the medical sector showing overall activity, particularly the medical device ETF (562600) which rose by 0.22% and has seen net inflows for 12 consecutive trading days [1] - Leading stocks in the medical device sector include Reborn Medical and Lide Medical, both of which rose over 10%, while Hualan Co., Bairen Medical, and Innotec also showed strong performance [1] - Lide Medical announced a major asset purchase plan to acquire 70% of Xiansheng Xiangrui for a transaction price of 1.733 billion yuan, constituting a significant asset restructuring as the target assets exceed 50% of the listed company's total assets [1] Group 2 - The long-term positive trend in the medical device sector remains unchanged, with the medical device ETF (562600) effectively capturing structural growth opportunities in the core medical fields [2] - The ETF tracks the CSI All Index Medical Device Index, which includes 100 representative listed companies in medical devices, medical services, and medical information technology [2] - Investors can also consider alternative options such as the Huaxia CSI All Index Medical Device ETF Initiated Link A (021250) and Link C (021251) for convenient investment [2]

Group 1 - The core point of the news is the performance and market position of Dongfulong Technology Group Co., Ltd., which saw a stock price increase of 5.11% to 17.89 CNY per share, with a total market capitalization of 13.701 billion CNY [1] - Dongfulong's main business involves the research, design, production, sales, and service of medical freeze-dryers and freeze-drying systems, with revenue contributions from various segments: 44.92% from the formulation division, 29.83% from the bioprocess division, 9.19% from the engineering division, 9.16% from the food division, 6.81% from after-sales service and parts, and 0.09% from others [1] Group 2 - According to data, Jin Xin Fund has a significant holding in Dongfulong, with its Jin Xin Shenzhen Growth Mixed A Fund increasing its stake by 156,300 shares in the third quarter, bringing the total to 2.3408 million shares, which represents 3.38% of the fund's net value [2] - The Jin Xin Shenzhen Growth Mixed A Fund has achieved a year-to-date return of 53.8%, ranking 873 out of 8140 in its category, and a one-year return of 40.89%, ranking 1139 out of 8056 [2] Group 3 - The fund managers of Jin Xin Shenzhen Growth Mixed A are Huang Biao and Yang Chao, with Huang having a tenure of 4 years and 176 days and a best return of 119.15% during his management period [3] - Yang Chao has a tenure of 4 years and 189 days, with a best return of 76.11% during his management period [3]

11月6日，深圳核心医疗的IPO申请获得受理，科创板第五套标准重启后，首家获得受理的创新医疗器械企业出现了。 核心医疗的主营产品是人工心脏，被誉为"医疗器械皇冠上的明珠"。2023年6月，其首发人工心脏产品Corheart 6获批上市，成为国内第四款获批 的人工心脏产品，也是最晚上市的国产产品。 但意外的是，核心医疗后来居上，2024年时Corheart 6的全国市占率超45%，位居行业第一。今年10月，Corheart 6完成第1000例植入，成为继雅培 HeartMate 3之后，全球第二款、中国首款突破千例大关的全磁悬浮人工心脏。 核心医疗也是国内人工心脏企业中资本化进程最快的公司，共经历6轮融资，投资方包括高瓴、正心谷等明星机构。目前，核心医疗是中国最接近 上市的人工心脏公司，有望冲刺"国产人工心脏"第一股。 市占率第一 人工心脏的主要应用场景是心衰。根据弗若斯特沙利文报告：2024年中国心衰患者人数超1500万人，其中终末期心衰患者超150万人。终末期心衰 从确诊到死亡的中位时间只有一年。 过去，这部分心衰患者只能进行心脏移植，但心脏供体可遇不可求。2024年中国心脏移植手术量只有1064例，大多数 ...

11月14日，英诺特涨5.16%，截至发稿，报35.89元/股，成交3683.44万元，换手率1.52%，总市值49.16 亿元。 医疗器械ETF（159883）基金经理为储可凡。 截至发稿，储可凡累计任职时间2年94天，现任基金资产总规模62.82亿元，任职期间最佳基金回报 103.17%， 任职期间最差基金回报-30.27%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，北京英诺特生物技术股份有限公司位于北京市丰台区海鹰路1号院6号楼1层2层、2号楼7层， 成立日期2006年2月6日，上市日期2022年7月28日，公司主营业务涉及POCT快速诊断产品研发、生产 和销售。主营业务收入构成为：呼吸道系列96.49%，其他试剂系列2.99%，优生优育系列0.51%。 从英诺特十大流通股东角度 数据显示，永赢基金旗下1只基金位居英诺特十大流通股东。医疗器械ETF（159883）三季度新进十大 流通股东，持有股数49.8万股，占流通股的比例为0 ...

中信保诚多策略混合(LOF)A（165531）成立日期2017年6月16日，最新规模11.33亿。今年以来收益 48.93%，同类排名1166/8140；近一年收益46.65%，同类排名762/8056；成立以来收益152.18%。 中信保诚多策略混合(LOF)A（165531）基金经理为王颖。 截至发稿，王颖累计任职时间8年274天，现任基金资产总规模49.04亿元，任职期间最佳基金回报 53.77%， 任职期间最差基金回报-8.42%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 11月14日，天益医疗跌5.04%，截至发稿，报60.80元/股，成交3032.49万元，换手率1.70%，总市值 35.84亿元。 资料显示，宁波天益医疗器械股份有限公司位于浙江省宁波市东钱湖旅游度假区莫枝北路788号，成立 日期1998年3月12日，上市日期2022年4月7日，公司主营业务涉及血液净化及病房护理领域医用高分子 耗材等医疗器械的研发、生产与销售。主营业务收入构成为：血液 ...

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-13 | 64.03 | -1.94% | -2040.35万 | -7.20% | 1280.76万 | 4.52% | 759.59万 | 2.68% | | 2025-11-12 | 65.30 11.34% | | -90.71万 | -0.31% | 1813.46万 | 6.16% | -1722.75万 | -5.85% | | 2025-11-11 | 58.65 -1.56% | | -233.23万 | -2.37% | 196.65万 | 1.99% | 36.59万 | 0.37% | | 2025-11-10 | 59.58 7.35% | | 450.32万 | 2.11% | -598.89万 | -2.80% | 148.57万 | 0.70% | | 2025-11-07 | 55.50 -4.31% | | -881.10万 ...

内容概要：经导管主动脉瓣置换术（TAVR）是指将人工主动脉瓣在体外压缩组装后，经导管输送并置 入到病变的主动脉瓣处，在功能上完成主动脉瓣置换的一种介入技术。自2002年4月世界首例TAVR、 2010年10月我国首例TAVR完成以来，国内外的TAVR器械研发及临床应用均取得快速发展。TAVR已成 为老年主动脉瓣狭窄（AS）和主动脉瓣反流（AR）患者的重要治疗手段。2024年国内共开展了TAVR 手术17232例（仅统计商业化植入，累计55083例），较2023年增长24.2%。2024年商业化植入TAVR的 前十省份为上海、四川、北京、广东、河南、浙江、山东、陕西、福建、江苏等地。从手术入路方式来 看，经股动脉（TF）途径是经导管主动脉瓣植入术的主要入路，占比为79.9%，其创伤性小，并发症发 生率低。其次为经心尖途径，占比18.4%，其余1.7%为其他入路方式。2021-2024年TAVR的器械成功率 持续上升，至2024年已达到96.16%。同时，TAVR围术期院内死亡率、术后30天死亡率、术后1年死亡 率均呈下降趋势，其他围术期事件的发生率也在稳定下降，显示出TAVR技术在安全性和有效性方面的 不断优化 ...